The Utility of SOX2 and AGR2 Biomarkers as Early Predictors of Tamoxifen Resistance in ER-Positive Breast Cancer Patients
Table 1
Clinicopathological characteristics of studied patients in relation to the three studied groups.
Group 1 (n = 124)
Group 2 (n = 48)
Group 3 (n = 52)
Test of sig.
Age (years)
Mean ± SD
51.4 ± 12.7
59.9 ± 10
59.5 ± 12.3
F = 12.899
<0.001
Median (min.–max.)
48 (28–77)
63.5 (39–77)
64 (36–78)
Histological type
Infiltrating lobular CA
16 (12.9%)
3 (6.3%)
9 (17.3%)
χ2 = 2.832
0.243
Infiltrating duct CA
108 (87.1%)
45 (93.8%)
43 (82.7%)
Pathological T stage
T1
78 (62.9%)
2 (4.2%)
32 (61.5%)
χ2 = 132.671
<0.001
T2
33 (26.6%)
12 (25.0%)
16 (30.8%)
T3
13 (10.5%)
5 (10.4%)
4 (7.7%)
T4
0 (0.0%)
29 (60.4%)
0 (0.0%)
Pathological N stage
N0
93 (75.0%)
2 (4.2%)
35 (67.3%)
χ2 = 80.737
<0.001
N1
24 (19.4%)
27 (56.3%)
14 (26.9%)
N2
7 (5.6%)
19 (39.6%)
3 (5.8%)
Grade
I
37 (29.8%)
2 (4.2%)
14 (26.9%)
χ2 = 17.005
0.002
II
64 (51.6%)
40 (83.3%)
28 (53.8%)
III
23 (18.5%)
6 (12.5%)
10 (19.2%)
Lymph vascular invasion
No
75 (60.5%)
10 (20.8%)
25 (48.1%)
χ2 = 21.797
<0.001
Yes
49 (39.5%)
38 (79.2%)
27 (51.9%)
Menopausal status
Pre
61 (49.2%)
11 (22.9%)
13 (25.0%)
χ2 = 14.968
0.001
Post
63 (50.8%)
37 (77.1%)
39 (75.0%)
Type of resistance
De novo
–
15 (31.3%)
0 (0.0%)
χ2 = 19.118
<0.001
Acquired
–
33 (68.8%)
52 (100.0%)
Presentation for failure
Distant metastases
–
–
11 (21.2%)
−
–
Recurrence
–
–
41 (78.8%)
Time to tamoxifen failure
Mean ± SD.
–
13.4 ± 6.8
23.1 ± 6.2
U = 373.50
<0.001
Median (min. – max.)
–
16 (2–24)
23 (14–44)
χ2: Chi square test. F: F for ANOVA test, Pairwise comparison bet. Each 2 groups was done using post hoc test (Tukey), U: Mann–Whitney test, : value for comparing between the studied groups, significant with group 1 and statistically significant at .
